Amryt, the Dublin-based orphan and rare disease drug firm, will have a market value of more than $300 million (€280 million) after its takeover of the US firm Aegerion.
Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion, which is emerging from bankruptcy protection in the US. The company is also seeking a listing on the...
Subscribe from just €1 per month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass